Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
Sponsor: Merck Sharp & Dohme LLC
Summary
Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.
Official title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
62
Start Date
2026-01-22
Completion Date
2026-04-09
Last Updated
2026-03-03
Healthy Volunteers
Yes
Conditions
Interventions
Ulonivirine
Oral tablet
Moxifloxacin
Oral tablet
Ulonivirine Placebo
Oral tablet
Moxifloxacin Placebo
Oral tablet
Locations (1)
ICON Early Phase Services (0001)
San Antonio, Texas, United States